Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Anticancer Drugs. 2020 Sep;31(8):759–775. doi: 10.1097/CAD.0000000000000962

Figure 5. GSK346294A effects on tumorigenesis and metastasis of TU-BcX-4IC PDX model.

Figure 5.

TU-BcX-4IC tumor pieces (3 × 3 mm) were implanted bilaterally in the mfp of SCID/Beige mice (5 mice/group). Mice were treated with intraperitoneal injections of DMSO vehicle or GSK346294A (25mg/kg bid) for 15 days. After 15 days, mice were sacrificed, and lungs and livers were harvested, fixed in formalin and embedded in paraffin, then sectioned and stained with H & E. Metastases were quantified. (A) Area of lung metastatic lesions per section and (B) overall number of metastases per section of DMSO treatment groups compared to GSK346294A. (C) Area of liver metastatic lesions per section and (D) overall number of metastases per section. (E) Representative images of the stained lung and liver sections of the DMSO control mice and GSK346294A treated mice. Error bars represent S.E.M.